Chris Giordano, Tenax Therapeutics CEO
Troubled times: With its back against the wall, little Tenax sends out an SOS while IMV takes out the budget axe, chops staff
The tally of restructurings in biotech continued to go up today with news from two small players that are in financial hot water.
Tenax Therapeutics …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
